JG
AMLX icon

Jefferies Group’s Amylyx Pharmaceuticals AMLX Stock Holding History

Jefferies Group’s Portfolio AMLX Stock Details AMLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		$625K Buy
+22,200
New +$554K 0.01% 958

Other funds holding AMLX

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Jefferies Group's AMLX Position: Q3 2022 in Review

Jefferies Group opened a new position in Amylyx Pharmaceuticals (AMLX) in Q3 2022: 2,791 shares worth $78.6K. The stake represents ﹤0.01% of the portfolio and ranks #1486 among its holdings.

95 funds tracked by Wall St. Rank hold AMLX as of Q3 2022.

  • Jefferies Group held 2,791 shares of Amylyx Pharmaceuticals worth $78.6K as of Q3 2022.
  • Amylyx Pharmaceuticals was a new Jefferies Group position in Q3 2022.
  • Amylyx Pharmaceuticals made up ﹤0.01% of Jefferies Group's portfolio in Q3 2022, its #1486 holding.
  • 95 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q3 2022.

Based on Jefferies Group's 13F filing for Q3 2022, filed 14 Nov 2022.